CANTON, MA, Conformation-X Therapeutics, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M.
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
